$385 Million is the total value of Aquilo Capital Management, LLC's 15 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 11.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $67,676,000 | +55.2% | 1,813,392 | +6.3% | 17.58% | +123.1% |
| SPRO | SPERO THERAPEUTICS INC | $53,456,000 | -5.2% | 3,829,209 | 0.0% | 13.89% | +36.4% | |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $39,451,000 | -4.1% | 448,512 | +6.0% | 10.25% | +37.9% |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $35,855,000 | +32.6% | 432,926 | +6.1% | 9.32% | +90.6% |
| QURE | Buy | UNIQURE NV | $35,651,000 | +10.8% | 1,157,513 | +21.2% | 9.26% | +59.2% |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $26,281,000 | -11.3% | 2,687,183 | +7.4% | 6.83% | +27.5% |
| NGM | Buy | NGM BIOPHARMACEUTICALS INC | $23,550,000 | -27.9% | 1,194,237 | +6.2% | 6.12% | +3.6% |
| RGNX | Buy | REGENXBIO INC | $23,133,000 | +21.2% | 595,444 | +6.4% | 6.01% | +74.3% |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS IN | $22,765,000 | +74.4% | 945,382 | +214.2% | 5.92% | +150.7% |
| AMYT | Buy | AMRYT PHARMA PLCsponsored ads | $13,828,000 | +24.1% | 1,140,000 | +42.5% | 3.59% | +78.4% |
| PIRS | Sell | PIERIS PHARMACEUTICALS INC | $12,243,000 | +29.6% | 3,196,527 | -13.0% | 3.18% | +86.4% |
| HARP | Sell | HARPOON THERAPEUTICS INC | $9,885,000 | -69.6% | 712,674 | -54.1% | 2.57% | -56.3% |
| GLPG | Buy | GALAPAGOS NVspon adr | $9,806,000 | +9.0% | 142,340 | +21.9% | 2.55% | +56.7% |
| ARGX | ARGENX SEsponsored adr | $6,383,000 | +9.3% | 21,200 | 0.0% | 1.66% | +57.3% | |
| GMAB | GENMAB A/Ssponsored ads | $4,900,000 | +24.4% | 120,000 | 0.0% | 1.27% | +78.8% | |
| XBI | Exit | SPDR S&P BIOTECH ETF TRput | $0 | – | -500,000 | -100.0% | -12.26% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -300,000 | -100.0% | -21.49% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.